Darzalex Continues to Advance in Multiple Myeloma

Two phase 3 trials led to Darzalex being granted a breakthrough therapy designation by the FDA. 
BY JASON M. BRODERICK @jasoncology
PUBLISHED: JULY 26, 2016
Darzalex (daratumumab) was granted a breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for use in combination with Revlimid /dexamethasone or Velcade /dexamethasone for patients with multiple myeloma who have had at least one prior therapy, according to the developers of the CD38-targeted antibody, Janssen and Genmab.

The designation, which will expedite the development and review of the Darzalex regimens, is based on two phase 3 trials. The phase 3 POLLUX trial demonstrated that combining Darzalex with Revlimid (lenalidomide) and dexamethasone reduced the risk of disease progression by 63 percent versus Revlimid and dexamethasone alone in patients with relapsed/refractory multiple myeloma. In the phase 3 CASTOR trial, adding Darzalex to Velcade (bortezomib) and dexamethasone reduced the risk of progression or death by 61 percent in patients with recurrent or refractory multiple myeloma.

“Despite tremendous progress in the past 15 years, multiple myeloma remains a highly complex and difficult disease to treat, with most patients relapsing or becoming resistant to therapy,” POLLUX lead author Meletios A. Dimopoulos, department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece, said in a statement. “Daratumumab has already shown pronounced activity as a monotherapy in heavily pretreated patients. This designation underscores the potential of daratumumab in combination with either a proteasome inhibitor or an immunomodulatory agent to provide much-needed benefit to patients with at least one prior therapy.”

The international, open-label POLLUX trial randomized 569 patients with relapsed/refractory multiple myeloma to Darzalex combined with Revlimid dexamethasone (286 patients) or Revlimid plus dexamethasone alone (283 patients). Darzalex was dosed at 16 mg/kg IV once weekly during cycles one and two, every two weeks during cycles three to six, and once only (on day one) of cycles seven onward. Oral Revlimid was administered at 25 mg daily for the first three weeks of each cycle and dexamethasone was dosed at 40 mg weekly (20 mg weekly in patients older than 75 or with a BMI less than 8.5). Treatment cycles for both study arms were 28 days. Patients were treated until progression or unacceptable toxicity.

The median patient age was 65 years. The median number of of prior treatment lines was one, with 19 percent of patients having received three or more lines of therapy. Eighty-six percent of patients had received a proteasome inhibitor; 55 percent had been treated with an immunomodulatory agent (IMiD), including 18 percent with Revlimid; and 44 percent had previously receiving both a proteasome inhibitor and an IMiD. Across the study population, 27 percent of patients were refractory to their most recent treatment and 18 percent were refractory to a proteasome inhibitor; however, no patients were refractory to Revlimid.

The primary endpoint of the study was progression-free survival (PFS), with secondary outcome measures including time to progression, overall response rate (ORR), overall survival and very good partial response (VGPR). At a preplanned interim analysis in May 2016, the study was unblinded after an independent panel determined the trial met its primary endpoint of improved PFS. Patients in the control arm were allowed to receive Darzalex at progression.



Talk about this article with other patients, caregivers, and advocates in the Myeloma CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Expert Talks Treating Newly Diagnosed Patients With Myeloma
The way that newly diagnosed patients with multiple myeloma is treated has changed significantly over recent years, especially as new drugs moved into the treatment realm for the disease, says Shaji K. Kumar, M.D.  
Improving Treatment for Elderly Patients With Myeloma
Several questions still remain regarding the treatment strategies for elderly patients with multiple myeloma, many of whom may have other comorbidities or trouble tolerating therapies.  
Individualized Treatment Needed for Relapsed, Refractory Multiple Myeloma
Patients with relapsed/refractory multiple myeloma should be given individualized treatment approaches guided by the biology of their disease, frailty of the patient and other comorbidities, said Natalie S. Callander, M.D., who presented on the topic at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.
Related Videos
Moving Mountains for Multiple Myeloma Kilimanjaro 2017
‚ÄčA team of patients, researchers, advocates and loved ones climbed Mount Kilimanjaro, Africa's highest mountain, to raise money for multiple myeloma awareness and research, benefitting the Multiple Myeloma Research Foundation.
MM4MM 2017 Kilimanjaro Team Training Climb
This year, a group of patients, advocates and health care professionals will tackle Mount Kilimanjaro to raise money and awareness for multiple myeloma.   
Chuck Wakefield Discusses Training for the Kilimanjaro Climb
Charles (Chuck) Wakefield, a multiple myeloma survivor and climber of the Moving Mountains for Multiple Myeloma Mount Kilimanjaro climb, discusses the importance of staying active and how he trained for the climb.
x
//For side ad protocol